These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17514802)

  • 61. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation.
    Libura J; Hoffmann T; Passweg J; Gregor M; Favre G; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 1999 Oct; 24(8):925-7. PubMed ID: 10516707
    [TBL] [Abstract][Full Text] [Related]  

  • 62. NCCN: Multiple myeloma.
    Traynor AE; Noga SJ;
    Cancer Control; 2001; 8(6 Suppl 2):78-87. PubMed ID: 11760563
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
    Bensinger WI
    Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma].
    Kosugi H
    Rinsho Ketsueki; 2015 Mar; 56(3):279-88. PubMed ID: 25876781
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Update on the treatment of multiple myeloma.
    Kyle RA
    Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tandem bone marrow transplantation in multiple myeloma.
    Murashige N; Kishi Y
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15070801
    [No Abstract]   [Full Text] [Related]  

  • 67. Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic.
    Amit O; Ram R
    Acta Haematol; 2018; 139(2):104-105. PubMed ID: 29414800
    [No Abstract]   [Full Text] [Related]  

  • 68. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 69. [The importance of autologous transplantation in multiple myeloma].
    Pour L; Hájek R; Adam Z; Krejcí M; Vorlícek J
    Vnitr Lek; 2009 Sep; 55(9):767-72. PubMed ID: 19785373
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple myeloma: future directions in autologous transplantation and novel agents.
    Hari PN; McCarthy PL
    Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S20-5. PubMed ID: 23290439
    [No Abstract]   [Full Text] [Related]  

  • 73. Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit all.
    Richardson PG
    Oncology (Williston Park); 2016 Aug; 30(8):747-9. PubMed ID: 27528243
    [No Abstract]   [Full Text] [Related]  

  • 74. Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma.
    Peggs KS; Mackinnon S; Yong K
    J Clin Oncol; 2002 Oct; 20(20):4268; author reply 4268-9. PubMed ID: 12377972
    [No Abstract]   [Full Text] [Related]  

  • 75. Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series.
    Atieh T; Hubben A; Faiman B; Valent J; Samaras CJ; Khouri J
    Ann Hematol; 2019 Oct; 98(10):2457-2459. PubMed ID: 31392460
    [No Abstract]   [Full Text] [Related]  

  • 76. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014.
    D'Souza A; Zhang MJ; Huang J; Fei M; Pasquini M; Hamadani M; Hari P
    Leukemia; 2017 Sep; 31(9):1998-2000. PubMed ID: 28663578
    [No Abstract]   [Full Text] [Related]  

  • 77. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
    Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bone marrow transplantation in multiple myeloma.
    Schlossman RL; Anderson KC
    Curr Opin Oncol; 1999 Mar; 11(2):102-8. PubMed ID: 10188074
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
    Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
    Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Bases of bone marrow transplantation: modalities and indications].
    García Laraña J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():14-21. PubMed ID: 10422446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.